4-[(5-amino-2-pyridinyl)oxy]-3-(1,1-dimethylethyl)benzonitrile | 1311138-97-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(5-amino-2-pyridinyl)oxy]-3-(1,1-dimethylethyl)benzonitrile
• 英文别名: 4-[(5-amino-2-pyridyl)oxy]-3-tert-butyl-benzonitrile；4-((5-Aminopyridin-2-yl)oxy)-3-(tert-butyl)benzonitrile；4-(5-aminopyridin-2-yl)oxy-3-tert-butylbenzonitrile
• CAS: 1311138-97-2
• 化学式: C₁₆H₁₇N₃O
• 分子量: 267.33
• InChiKey: CYQIUMOWTIJUGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  71.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS
  申请人：Alvaro Giuseppe

  公开号：US20130267510A1

  公开（公告）日：2013-10-10

  The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

  该发明提供了化合物的公式(I)：所述化合物是Kv3通道的抑制剂，可用于预防或治疗相关疾病。
• [EN] IMIDAZOLIDINEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLIDINEDIONE
  申请人：GLAXO GROUP LTD

  公开号：WO2011069951A1

  公开（公告）日：2011-06-16

  The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

  这项发明提供了化合物(Ia)及其药学上可接受的盐。该发明还提供了将这些化合物或盐用作Kv3.1和/或Kv3.2的调节剂，以及在需要Kv3.1和/或Kv3.2调节剂的疾病或紊乱的治疗中的用途，如抑郁症和情绪障碍、听觉障碍、精神分裂症、物质滥用障碍、睡眠障碍或癫痫病。
• KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3901152A1

  公开（公告）日：2021-10-27

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, Y1 to Y4 and R1 to R6 are as described herein.

  这项发明提供了具有一般式(I)的新杂环化合物 其中A、B、L、Y1至Y4和R1至R6如本文所述。
• BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
  申请人：AUSPEX PHARMACEUTICALS, INC.

  公开号：US20140206713A1

  公开（公告）日：2014-07-24

  The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及新的囊泡单胺转运体2（VMAT2）苯并喹啉抑制剂，其制药组合物以及使用方法。
• IMIDAZOLIDINEDIONE DERIVATIVES
  申请人：Alvaro Giuseppe

  公开号：US20120289526A1

  公开（公告）日：2012-11-15

  The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy.

  本发明提供了公式（Ia）的化合物及其药学上可接受的盐。本发明还提供了将该化合物或盐用作Kv3.1和/或Kv3.2调节剂以及治疗需要Kv3.1和/或Kv3.2调节剂的疾病或障碍，例如抑郁和情绪障碍，听力障碍，精神分裂症，物质滥用障碍，睡眠障碍或癫痫。